US equities
|
MU
$885.12
▼-3.17%
NVDA
$215.96
▼-2.41%
SNDK
$1,312.80
▼-6.45%
SPCX
$145.10
▼-4.64%
AMD
$536.66
▼-5.98%
INTC
$91.77
▼-6.48%
TSM
$414.75
▼-3.55%
AAPL
$344.88
▲+0.56%
MU
$885.12
▼-3.17%
NVDA
$215.96
▼-2.41%
SNDK
$1,312.80
▼-6.45%
SPCX
$145.10
▼-4.64%
AMD
$536.66
▼-5.98%
INTC
$91.77
▼-6.48%
TSM
$414.75
▼-3.55%
AAPL
$344.88
▲+0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.350
+0.050 (+3.85%)
Delayed Quote
Updated: 10:31 AM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
↗
December 17, 2022
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are...
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
↗
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
↗
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Expert Ratings for Allogene Therapeutics
↗
September 22, 2022
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
↗
December 12, 2022
Via
Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 29, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 02, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 31, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 11, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 06, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Apple, Amazon, HP And Other Big Losers From Friday
↗
August 29, 2022
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
↗
September 22, 2022
Gainers
Via
Benzinga
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
↗
August 10, 2022
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
↗
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
↗
August 10, 2022
Via
Benzinga
Allogene Therapeutics: Q2 Earnings Insights
↗
August 09, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
↗
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
↗
July 15, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 15, 2022
Via
Benzinga
89 Biggest Movers From Friday
↗
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
↗
June 03, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
↗
June 03, 2022
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 17, 2022
Via
Benzinga
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
↗
May 10, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
